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Camptothecin and doxorubicin belong to a family of anticancer drugs that exert cytotoxic effects by triggering apoptosis in various cell types.
However there have only been few investigations showing that matricellular proteins like thrombospondin-1 (TSP-1) could be involved in the
underlying mechanism of this cytotoxicity. In this report, using Hoechst reagent staining, reactive oxygen species production and caspase-3
activity measurement, we determined that both camptothecin and doxorubicin induced apoptosis in human thyroid carcinoma cells (FTC-133). On
the one hand, we demonstrated that camptothecin and doxorubicin inhibited TSP-1 expression mainly occurring at the transcriptional level. On the
other hand, drug-induced apoptosis determined by western blot analysis for PARP cleavage and caspase-3 activity measurement, was significantly
decreased in presence of exogenous TSP-1. In order to identify the sequence responsible for this effect, we used the CD47/IAP-binding peptide
4N1 (RFYVVMWK), derived from the C-terminal domain of TSP-1, and known to play a role in apoptosis. Thus, in presence of 4N1,
camptothecin and doxorubicin-induced pro-apoptotic activity was considerably inhibited. These findings suggest that induction of apoptosis by
camptothecin or doxorubicin in FTC-133 cells is greatly dependent by a down-regulation of TSP-1 expression and shed new light on a possible
role for TSP-1 in drug resistance.
© 2006 Elsevier B.V. All rights reserved.Keywords: 4N1; Camptothecin; Doxorubicin; Apoptosis; Thyroid carcinoma cell1. Introduction
The thyroid gland is necessary for the development and
homeostasis of vertebrates [1]. However, numerous thyroid
pathologies exist including benign thyroiditis and thyroid
carcinoma which represents the most common endocrine
malignancy, accounting for the majority of deaths from
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doi:10.1016/j.bbamcr.2006.08.0011986, an important number of thyroid cancers was diagnosed
particularly in children. The incidence rate has been multiplied
by 10 between 1990 and 2000 depending on the exposure area
and an important number of new cases over the next 50 years
are expected [2]. Conventional therapy consists of surgical
resection, radioiodine 131I therapy, TSH-suppressive thyroxin
treatment and additional chemotherapy in the case carcinoma
became insensitive to iodine therapy [3,4]. Among the cytotoxic
compounds pointed out as potent therapeutics against cancer,
we used camptothecin and doxorubicin. Camptothecin acts as a
DNA topoisomerase I inhibitor that blocks DNA synthesis [5].
Doxorubicin is an anthracycline having multiple potential
mechanisms of action including inhibition of DNA topoisome-
rase I and II, inhibition of helicases, generation of toxic free
radicals, alteration of membrane structure and function and
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described to induce apoptosis in different cell types [9–13].
Apoptosis plays an important role during development and
normal turn-over of adult tissues and a decrease in the rate of
apoptosis might have severe pathological consequences that
facilitate tumor growth [14]. Thus, apoptosis appears to confer
little obvious therapeutic benefit and several anticancer drugs
exert their cytotoxic effect by this way [15].
Some of our previous studies evidenced that modification in
the expression of the matricellular multidomain glycoprotein
thrombospondin-1 (TSP-1) could play a critical role in the
regulation of thyroid cell proliferation, migration and invasion
[16]. The role of this protein in cancer and apoptosis is both
complex and controversial [17], conflicting functions are
described, TSP-1 being either pro- or anti-apoptotic according
to cell type [18,19]. Moreover, a peptide derived from the C-
terminal domain of TSP-1 (4N1) has been proposed to play a
role in apoptosis [20]. This VVM motif-containing peptide
mediates its effects through the binding to integrin-associated
protein CD47 [21].
In the present work, we studied the apoptotic effects of
doxorubicin and camptothecin in a poorly differentiated
follicular thyroid carcinoma cell line FTC-133, showed the
effects of these drugs on TSP-1 expression and secretion and
evidenced a potential anti-apoptotic role for TSP-1 in this cell
line. Moreover, the C-terminal globular domain of TSP-1 that
binds to integrin-associated protein (IAP or CD47) was shown to
play an important role in the observed protective effect of the
protein.2. Materials and methods
2.1. Materials
Doxorubicin was obtained from Farmitalia (Milano, Italy). TSP-1 was
from Calbiochem. 4N1 (RFYVVMWK) was purchased from BACHEM
(Weil am Rhein, Germany), 4NGG peptide (RFYGGMWK) was synthesized
by Dr. Patigny IFR 53 and anti-CD47 antibody B6H12 from BD Biosciences
(Le Pont de Claix, France). Dulbecco's modified Eagle's medium/F-12 and
trypsin were purchased from Invitrogen (Cergy Pontoise, France). Bovine
foetal serum was from Dutscher (Brumath, France). PARP (#9542) antibodies
were from Cell Signaling (Beverly, USA). Monoclonal TSP-1 Ab-11
antibodies (#MS-1066) were from Labvision. β-actin antibodies (A5441)
were from Sigma. ECL western blotting detection reagents was from
Amersham (Freibourg, Germany). All other products, including camptothe-
cin, were from Sigma (St. Louis, MO, USA).
2.2. Cell line and culture conditions
FTC-133 is a human follicular thyroid carcinoma derived cell line (ECACC
94060901) obtained from a lymph node metastasis of a single patient [22]. This
cell line expresses most proteins present in differentiated thyroid tissue such as
thyroglobulin (Tg), thyrotropin receptor (TSHr), thyroid transcription factors
TTF-1 or Pax-8 [23,24]. However, it does not express TPO and hNIS like many
thyroid cancers [24]. Moreover FTC-133 exhibit a p53 mutation which seems to
confer cells the ability to grow in culture [25]. Cells were routinely grown in
Dulbecco's modified Eagle's medium/F-12 (1:1) supplemented with 10% heat-
inactivated foetal calf serum, 100 μg/mL streptomycin and 100 IU/mL
penicillin. Cells were cultured in 75 cm2 flasks at 37 °C in a 5% CO2–95%
air–water saturated atmosphere. Trypsinization was performed at confluence.
Isolated cells were then cultured in 96-well culture plates for cell viability andluciferase assay and in 6-well culture plates for western blot analysis, mRNA
extraction, caspase assay or Hoechst staining. Experiments were performed
during the exponential phase of cell growth and each control is a DMSO control.
2.3. Cell viability determination
Cells were plated in microwell plates at 104 cells/mL and incubated until they
reached the logarithmic growth phase. The spent medium was aspirated from
cells and replaced with serum free medium. After 24 h incubation, camptothecin
or doxorubicin was added. At indicated times, 10% (v/v) UptiBlue (Uptima,
Interchim, Montluçon, France) was added. Plates were incubated for an
additional 3 h and reduction was then measured spectrofluometrically (λex:
530–560 nm; λem: 590 nm). Results were calculated as percent of controls as
follows: (Experimental absorbance /untreated control absorbance)×100.
2.4. Hoechst reagent staining
Cell monolayers cultured as described above were treated with 5 μM
camptothecin or doxorubicin for 12 h. Cells were then stained with propidium
iodide (10 μg/mL) and Hoechst 33258 reagent (20 μg/mL) for 15 min at room
temperature and photographed under fluorescence microscopy (λex: 351.1–
363.8 nm; λem: 390–480 nm). Apoptotic cells, which contained condensed
chromatin fragments, were scored in three replicate wells for each treatment and
each assay was repeated at least three times. Results are expressed as percentage
of the total cell number.
2.5. Spectrofluorimetric assay of ROS production
Cells treated for 0 to 6 h in the presence of 5 μMcamptothecin or doxorubicin
and untreated control cells, were incubated with 2 μM of dihydroethidium (λex:
360 nm; λem: 420 nm) for 10 min, washed with phosphate-buffered saline, and
then analysed by spectrofluorometry in RPMI-1640mediumwithout phenol red.
In the presence of ROS, dihydroethidium is oxidized to ethidium and fluoresces
in red (λem: 640 nm). The 640/420 nm fluorescence intensity ratio permits to
measure the production of ROS in living cells.
2.6. Caspase-3 activity
After incubation, cell pellets were washed twice with PBS and scrapped with
ice-cold lysis buffer as provided by Promega (caspACE assay kit) and caspase-3
activity was measured accordingly: 50 μg of cytosolic fraction were incubated
with caspase-3 colorimetric substrate that absorbs at 405 nm following its
cleavage. Absorbance was measured with a multichannel plate reader
(Metertech. inc. Σ960).
2.7. Western blotting
Cultured cells were made quiescent by serum starvation for at least 24 h
before treatment. Conditioned media were collected, centrifuged at 3000×g for
5 min and total protein was measured using BCA assay from Uptima (Interchim,
Montluçon, France). Cells were then washed with ice-cold PBS, lysed in ice
cold buffer containing 10 mM Tris pH 7.4, 150 mM NaCl, 5 mM EDTA, 1 mM
Na3VO4, 1 mM dithiothreitol, 10 μg/mL leupeptin, 10 μg/mL aprotinin, 10%
glycerol, 1% Brij (v/v), placed on ice for 20 min and then centrifuged at
14,000×g for 15 min at 4 °C. Equal amounts of proteins (conditioned media or
whole cell extracts) were resolved by 10% SDS-PAGE gels and transferred to
nitrocellulose membranes and probed with the appropriate antibodies (mono-
clonal anti-TSP-1: dilution 1/400, polyclonal anti-PARP: dilution 1/1000, or
anti-β-actin antibodies: dilution 1/8000). Horseradish peroxidase-conjugated
goat anti-rabbit or anti-mouse IgG were used as secondary antibodies (dilution
1/4000 and 1/10,000 respectively) and proteins were detected using an enhanced
chemiluminescence (ECL) kit.
2.8. Transfection and luciferase assay
FTC-133 cells (5×106) grown in 96 well microplates (PerkinElmer), were
transiently transfected with the pGL3-TSP-1 promoter sequence − 1290/+ 750
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reagent following the protocol provided by the supplier (Life Technologies,
Rockville, MD, USA). One hour following transfection, cells were treated or
not with camptothecin or doxorubicin at the concentrations and times as
indicated. At the end of the incubation, cells were washed with PBS, lysed with
100 μl FireLite dual reporter lysis buffer (PerkinElmer Life Sciences, France)
and luciferase activities were measured with the PerkinElmer TopCount
microplate counter.
2.9. Reverse transcription-polymerase chain reaction
RT-PCR was performed on total RNA prepared by RNeasy® Mini kit
(QIAGEN). 1 μg of total RNA was reverse transcribed using AMV reverse
transcriptase and oligo(dT)15 primer from Promega. Amplification was
performed using PCR Master Mix and Taq DNA polymerase from Promega.
The optimal reaction conditions were: 30 cycles, 56 °C for TSP-1 and 25 cycles,
50 °C for S26. Specific primer pairs were, for TSP-1: forward 5′-CTC AGG
AAC AAA GGC TGC TC-3′ reverse: 5′-ACT CCT GAATGT GGC AGG TC-
3′; for S26: forward 5′-GTG CGT GCC CAA GGA TAA GG-3′, reverse 5′-
ATG GGC TTT GGT GGA GGT CG-3′.
2.10. Statistics
Data are mean±S.D. of three independent experiments (Student's t test), p
levels of <0.05 were considered significant.3. Results
3.1. Camptothecin and doxorubicin affected FTC-133 cell
viability in a time-dependent manner
The potential cytotoxic effects of camptothecin and doxor-
ubicin on FTC-133 thyroid carcinoma cells were assessed using
the UptiBlue viable cell counting assay, as described inMaterials
and methods. The cells were treated with various doses of each
drug for different times (3, 6, 12 or 24 h). As indicated in Fig. 1,
both camptothecin and doxorubicin exhibited cytotoxic effects
in a time-dependent manner when used at a final concentration
of 5 μM. Although lower doses from 0.5 μM also decreased cellFig. 1. Effect of camptothecin and doxorubicin on cell viability. FTC-133 cells
were incubated with either 5 μM camptothecin or 5 μM doxorubicin for the
indicated times. Cell viability was determined by Upti-blue assay as described in
Materials and methods. Results are expressed as percent of control and represent
means±standard deviations (S.D.) of at least three independent experiments.viability (unpublished data), we decided to use each drug at
5 μM for the following investigations to reach nearly 50% cell
death after 12 h stimulation.
3.2. Camptothecin and doxorubicin induced thyroid carcinoma
cell apoptosis
FTC-133 cells were incubated with or without camptothe-
cin or doxorubicin for 12 h. Cells were double stained with
propidium iodide and Hoechst reagent and examined by
microscopy (Fig. 2A). When exposed to both drugs, FTC-133
cells appeared highly susceptible to apoptosis. Thyroid
carcinoma cells indeed exhibited the distinctive morphology
of apoptotic cells including nuclear shrinkage and desegrega-
tion (42±2% in drug treated cells versus 0% in control cells).
To confirm that these observed morphological changes were
caused by apoptosis induction, similarly treated-cells were
used to quantify the reactive oxygen species (ROS) produc-
tion, known to play a main role in apoptosis induction, [26]
(Fig. 2B) and the caspase-3 activity (Fig. 2C). The capacity of
both drugs to induce an oxidative stress was investigated using
the fluorescent probe dihydroethidium. Indeed, Fig. 2B
showed that both drugs were able to induce ROS production
as soon as 4 h, reaching nearly 140% after 6 h of treatment.
Moreover, as shown in Fig. 2C, both camptothecin and
doxorubicin increased the cleavage of caspase-3 substrate up
to four-fold after 8 h incubation, reporting an acute caspase-3
activity.
3.3. Effect of camptothecin and doxorubicin on TSP-1
expression and secretion
Quiescent FTC-133 cells were transiently transfected with
the pGL3-basic vector containing the − 1290/+ 750 sequence of
the human TSP-1 promoter inserted upstream of the firefly
luciferase gene [27,28]. These thyroid carcinoma cells were
treated with or without camptothecin or doxorubicin for
different times (Fig. 3A). The results showed a significant
decrease in the luciferase activity from 3 h for doxorubicin
(15% inhibition) and from 6 h for camptothecin (15%
inhibition). At 12 h, the remaining luciferase activity was
only 20% in camptothecin-treated cells and 5% in doxorubicin-
treated cells as compared to control. The decrease in TSP-1
promoter gene activity induced by both drugs was correlated
with a reduction in TSP-1 mRNA expression and protein
secretion (Figs. 3B and C). After 8 h of treatment, TSP-1
mRNA expression was reduced with camptothecin and
completely inhibited in the presence of doxorubicin (Fig. 3B).
In addition, using Western blot analysis, we measured a two-
fold reduction in the secretion of TSP-1 protein after 12 h
incubation with camptothecin or doxorubicin and no more
secreted TSP-1 was detected from 24 h while β-actin kept a
steady state level (Fig. 3C). These results led us to investigate
whether TSP-1 could play a pivotal role in the apoptotic
program triggered by camptothecin and doxorubicin. To address
this question, we used purified human TSP-1 for further
investigations.
Fig. 2. Evaluation of the effect of camptothecin and doxorubicin on apoptosis induction. (A) Morphologic examination after Hoechst and propidium iodide staining of
FTC-133 cells cultured for 12 h alone (Ctrl) or in the presence of either 5 μM camptothecin (Cpt) or 5 μM doxorubicin (Dox). Original magnification ×200. Scale bars,
50 μm.White arrows indicate apoptotic bodies. (B) ROS production in drug-treated cells. FTC-133 cells were treated for the indicated periods with 5 μMcamptothecin
or 5 μM doxorubicin before incubation with 2 μM dihydroethidium for 10 min. Data were normalized with respect to control values and results are expressed as
percentage of initial ROS amount set at 100%. Results are given as means±S.D. of three independent experiments. (C) Effect of camptothecin and doxorubicin on
caspase-3 activity. FTC-133 cells were treated for the indicated times with 5 μM camptothecin or 5 μMdoxorubicin. Caspase-3 activity was determined as described in
Materials and methods. Results are expressed in pmol pNA (para-nitroaniline) liberated per hour and per μg protein and are shown as means±S.D. of three
independent experiments.
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carcinoma cell apoptosis
PARP, is known to facilitate cellular disassembly, remains
one of the main cleavage targets of caspase-3 in vivo and is
considered as a good marker for cells undergoing apoptosis. As
shown in Fig. 4A, treatments with camptothecin or doxorubicin
for 8 h induced PARP cleavage. An upregulation of PARP
expression was observed mainly under doxorubicin treatments,
as frequently reported when using such toposiomerase [8].
When the cells were pre-treated 30 min with TSP-1 before drug
addition, PARP cleavage was not any more detected indicating
that TSP-1 was capable of preventing the drug-induced PARP
processing. Moreover, the caspase-3 activity was assessed in
similar conditions (Fig. 4B). The results showed that TSP-1protected carcinoma cells from camptothecin or doxorubicin-
induced caspase-3 activation.
3.5. Effect of 4N1 peptide on camptothecin or doxorubicin-
induced apoptosis
It has been demonstrated that the biological effect of TSP-1
was connected to its binding to cell surface receptors such as
CD47 or CD36 [29,30]. In FTC-133 cells, a high level of CD47
receptor expression compared to a low level of CD36 was
detected (data not shown). Further experiments were also
carried out using the CD47 agonist peptide RFYVVMWK
(4N1), derived from the C-terminal domain of TSP-1, and the
scramble peptide 4NGG (RFYGGMWK) that served as control
peptide [21]. Furthermore, to determine whether the CD47
Fig. 3. Effect of camptothecin and doxorubicin on TSP-1 expression and secretion. (A) Quiescent FTC-133 cells transiently transfected with the − 1290/+ 750 bp TSP-
1 promoter construct were treated for the indicated times without or with 5 μM camptothecin or 5 μM doxorubicin. Luciferase activities are expressed in relative units
to drug stimulation. Basal luciferase activity (DMSO stimulated sample) was established as 100%. The data are shown as the means±standard deviations (S.D.) of at
least three independent experiments. SD bars marked with asterisks differ significantly (Student's t test) from control (*p<0.05, ***p<0.001, ns, non-significant). (B)
FTC-133 cells treated with camptothecin or doxorubicin for 8 h were used for TSP-1 mRNA expression. The constitutively expressed S26 “housekeeping” gene was
used as a normalizing control. (C) Cells treated for 12 and 24 h were used to study TSP-1 protein secreted in the culture medium byWestern blot. β-actin antibody was
used as a control.
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of cell apoptosis, the blocking anti-CD47 antibody B6H12 [31]
was used. Effects of the peptides and B6H12 antibody on FTC-
133 cell growth were assessed by using UptiBlue viable cell
counting assay, as described in Materials and methods. Cells
were treated with both drugs in addition of 4NGG, 4N1, or 4N1
and B6H12 for various periods (3, 6, 12 or 24 h). The results
presented in Fig. 5 showed that 4NGG scramble peptide
exhibited no effect on camptothecin or doxorubicin-induced
growth arrest. On the contrary, 4N1 treatment protected cells
from camptothecin and doxorubicin-induced growth arrest. In
the presence of B6H12 antibody, the 4N1 peptide became
unable to prevent the drug-dependent inhibition of cell growth,
thus demonstrating the molecular role of CD47 in the observed
4N1 protective effect. Moreover, western blot analysis (Fig. 6A)
showed that in the presence of the 4N1 peptide, the cleaved
PARP fragment was not any more detected in FTC-133 cells
treated with camptothecin or doxorubicin. In the presence of
B6H12, the 4N1 peptide did not prevent the camptothecin or the
doxorubicin-induced PARP cleavage. These results wereconfirmed by measuring caspase-3 activity under the same
conditions (Figs. 6B and C). Indeed, in presence of the 4N1
peptide, the camptothecin-induced caspase-3 activity was
abolished and the treatment with 4N1 alone (without drug)
exhibited no effect on caspase-3. The same effect in a lesser
extend was observed when 4N1 was used in combination with
doxorubicin, thus indicating that this treatment remained
significant in preventing doxorubicin-induced caspases-3
activity. As previously observed for cell growth and PARP
processing, blocking the CD47 membrane receptor avoided the
protective effect of 4N1 on drug-stimulated caspase-3 activity.
Identical results were obtained by quantifying the 17 kDa
cleaved caspase-3 pro-apoptotic form by immunoblotting (data
not shown).
4. Discussion
The role of thrombospondin in the process of programmed
cell death has recently came into focus and attracted much
attention from scientists interested in altering the behavior of
Fig. 4. Effect of TSP-1 on camptothecin and doxorubicin induced apoptosis.
Both PARP cleavage (A) and caspase-3 activity (B) were analysed. Cells were
treated for 8 h in the absence or presence of 5 μM camptothecin, 5 μM
doxorubicin or 2 μM TSP-1 alone or combined. PARP cleavage was determined
by Western blot analysis and caspase-3 activity was measured as described in
Materials and methods. Results are expressed in pmol pNA liberated per hour
and per μg protein and are shown as means±S.D. of three independent
experiments. S.D. bars marked with asterisks differ significantly from control
(**p<0.01, ***p<0.001, ns, non-significant). S.D. bars marked with circles
differ significantly from the corresponding values without TSP-1 (°°p<0.01).
Fig. 5. Effect of 4N1 on camptothecin- and doxorubicin-induced growth
inhibition. FTC-133 cells were incubated with either camptothecin or
doxorubicin at 5 μM along with 100 μM 4N1 or 4NGG and B6H12 antibody
at 100 μg/ml for the indicated times. Cell viability was determined by Upti-blue
assay as described in Materials and methods. Results are expressed as percent of
control and represent means±standard deviations (S.D.) of at least three
independent experiments.
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TSP-1-derived peptide 4N1 exhibited anti-apoptotic properties
against thyroid tumoral cells and decreased sensitivity to
apoptosis induced by camptothecin and doxorubicin.
First, we demonstrated that treatment of human thyroid
carcinoma cells with camptothecin or doxorubicin led to
elevated cytotoxic events associated with reactive oxygen
species generation and correlated to an increased caspase-3
activity and induced PARP processing. This is in agreement
with other data supporting that the mechanism of cell death
mediated by camptothecin or doxorubicin were related to
apoptosis in a range of human metastases diseases such as T-cell
lymphoma, colorectal, breast, ovarian, renal or prostate cancer
cells [32–34]. However, in the context of thyroid diseases,
camptothecin has only been investigated until today in the
treatment of medullary thyroid carcinoma (MTC) representing
only 5% of all thyroid malignancies, but never in metastaticthyroid follicular carcinoma (FTC) [35]. Doxorubicin is
recognized as the most effective cytotoxic drug against
anaplasic thyroid carcinoma (ATC), one of the most aggressive
human malignancies, and therefore this drug is extensively used
to cure thyroid cancer [36,37]. However, to our knowledge,
only two investigations were really interested to determine
whether doxorubicin treatments cause cell apotosis in follicular
thyroid carcinoma (FTC) and the corresponding results
remained highly controversial [38,39]. Indeed, although
Yeung and collaborators [38] failed to detect a doxorubicin-
induced cell death in FTC cells, Massart and colleagues [39]
developed the concept of a doxorubicin-induced Fas-mediated
apoptosis corroborating our results.
Second, we demonstrated for the first time that camptothecin
or doxorubicin-induced apoptosis was correlated with TSP-1
down regulation, mainly occurring at the transcriptional level.
Similarly, a recent investigation conducted in our laboratory
underlined that overexpression of the PTEN tumor-suppressor
gene leading to induction of thyroid carcinoma apoptosis was
also correlated with a significant down-regulation of TSP-1
expression at both RNA and protein levels [16]. These results
Fig. 6. Effect of 4N1 peptide on camptothecin or doxorubicin induced apoptosis. Cells were treated for 8 h. Camptothecin or doxorubicin were present as
indicated at 5 μM along with 100 μM 4N1 or 4NGG and B6H12 antibody at 100 μg/ml. Western blot analysis was performed for PARP cleavage (A) and
Caspase-3 activity was measured as described in Materials and methods (B and C). Results are expressed in pmol pNA substrate liberated per hour and per μg
protein and are shown as means±S.D. of three independent experiments. SD bars marked with asterisks differ significantly from control (*p<0.05, **p<0.01,
***p<0.001, ns, non-significant).
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FTC cells. For the first time our results shed new light on the
anti-apoptotic properties of both the mature TSP-1 protein and
the synthetic TSP-1-derived peptide 4N1 in thyroid cancer. We
provided evidences that both treatments were capable of
inhibiting cell death triggered by camptothecin and doxorubicin
by interfering with the caspase-3 pathway. Consistent with
recent observations [40], we identified the CD47 receptor as
potential membrane protein relaying 4N1-mediated control of
tumor cell death; CD36 being undetectable under our experi-
mental conditions (data not shown). In opposite to our findings,the main recent laboratory analyses reported a critical function
for TSP-1 in the stimulation of cell apoptosis in several
cancerous cells and tissues [41–44]. For example, recent data
supplied proofs that TSP-1 exerted direct pro-apoptotic effects
on leukaemia cells by means of a caspase-dependent mechan-
ism mediated by CD36 [45] or by a caspase-independent way
depending to CD47 binding [45,46]. Additionally, although we
observed that TSP-1 dramatically decreased the efficiency of
camptothecin-induced apoptosis in thyroid carcinoma, others
proposed that TSP-1 could be used in combination with
campthotecin analogues to increase inhibition of tumor growth
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with synthetic peptides derived from TSP-1 designated them as
strong inducers of tumor cell death but focused mostly on two
heparin-binding peptides located within the NH2-terminal and
type 1 repeats [42,48]. In this study, we were mostly interested
in the biological activity of the TSP-1-derived C-terminal 4N1
peptide. In the light of these results, the TSP-1-dependent
regulation of cancer cell death must be cautiously apprehended.
Indeed, it seems to be directly related to the nature of the
synthetic TSP-1-derived peptide and to the differential
distribution of the specific membrane receptors that directly
depends on the cellular context.
Cancer cell resistance to chemotherapy is a major concern in
clinical oncology, resulting in reduced cancer cell apoptosis,
increased tumor growth and decreased patient survival. Thyroid
cancers are considered as highly chemoresistant malignancies
what engaged most of the non-surgical therapeutic efforts on
radioiodine therapy [49]. Here, we developed the concept that
the levels of TSP-1 could directly drive the thyroid cancer
resistance to doxorubicin treatment, thus impairing the
efficiency of such chemotherapy in clinical practice [39,50].
This is in agreement with recent data showing that FTC238
thyroid cells, exhibiting a higher endogenous TSP-1 level than
FTC133, were the least sensitive to doxorubicin treatment [39].
Consistent with our results, TSP1 was previously linked to
disease recurrence and decreased patient survival [17,51]. For
example, TSP-1 was recently considered as a poor prognostic
factor for survival in colorectal metastases [52] and in invasive
bladder cancer [53]. Some reports investigated TSP-1 expres-
sion level in clinical thyroid cancer cases. One study showed no
significant difference in mean TSP-1 mRNA expression in in
vivo thyroid cancers in comparison to normal specimens [54].
However, another study demonstrated that TSP-1 expression
was reduced in correlation with the increasing aggressiveness of
different thyroid lesions [55]. Another report evaluating 75
papillary thyroid cancers, demonstrated that TSP-1 expression
was inversely correlated with invasiveness [56]. Moreover, this
contradictory theory was evoked in other cell system and
several approaches that were designed to increase the levels of
thrombospondin are being developed for the treatment of cancer
[57]. Indeed, patients with TSP-1-negative tumors appeared to
present a poor prognosis in colon cancer [58] and over-
expression of TSP-1 in mice lacking endogenous TSP-1 was
reported to suppress tumor growth [59]. Additionally, 4N1-
containing proteins in tumor tissues were considered as a
predictive marker for patient survival with renal carcinoma
since 4N1-positive tumors were locally confined and of
remarkably smaller size [60]. Recent studies described that
some cancers may develop the ability to counterbalance their
own secretion of pro- or anti-tumoral factors [61–63] which
could explain the apparent conflicting results. Some tumor cells
were shown to bypass the expected inhibitory effect of TSP-1.
For exemple, human breast cancer cells could override the
antiangiogenic effects of TSP-1 in vivo by increasing vascular
endothelial growth factor (VEGF) expression [64]. Scarpino et
al. [65] demonstrated that TSP-1 expression was under the
control of hepatocyte growth factor (HGF) in papillary thyroidcarcinomas and in malignant gliomas overexpression of TSP-1
and TGFβ increase the biologic malignancy [66]. In FTC-133
cells, a continuous inhibition of TSP-1 under drug treatment
was observed and addition of TSP-1 or its derived peptide 4N1
in camptothecin- or doxorubicin-treated cells exhibited an
unexpected anti-apoptotic effect. Whether other growth factors
are implicated remains to be demonstrated. Altogether, accord-
ing to the cellular environment specificity, TSP-1 could be
either significantly associated with a worse prognosis or
considered as an interesting marker for survival in human
metastases.
Finally, our results provide new information that may explain
one component of the drug-resistance phenotype in thyroid
tumoral diseases and support the idea that TSP-1 could be
helpful for predicting recurrence and survival outcome in
patients affected by such pathologies. Understanding how
biological factors such as TSP-1 are capable of driving
chemotherapy resistance and decreasing patient survival only
in some cancers will be of great interest during the next years to
potentially enhance therapeutic response and to identify the best
clinical protocol to be used for each patient, improving efficacy
and tolerance.
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